GlassScriptPhysician profile
Manuel J Pardo
NPI 1366699423
$149,127.26
in general payments reported to CMS, 2019-2025
22 companies · $35K in 2025
The $35K reported for 2025 was more than what 97% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $4,752 · 2021: $5,671 · 2022: $5,653 · 2023: $30K · 2024: $56K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Food and Beverage: $11K · Travel and Lodging: $9,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,545.00 |
| Food and Beverage | $10,780.97 |
| Travel and Lodging | $9,384.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $72,726.25 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $72,349.14 | 2019-2025 | Biktarvy, Yeztugo, Descovy |
| Janssen Biotech, INC. | $702.58 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $625.86 | 2019-2025 | Serostim, Serostim |
| Merck Sharp & Dohme LLC | $471.76 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $329.49 | 2019-2025 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $316.30 | 2019-2024 | Mytesi |
| Neurocrine Biosciences, INC. | $302.48 | 2024-2025 | Ingrezza |
| Amgen INC. | $285.46 | 2020-2025 | Repatha, Otezla, Otezla |
| Antares Pharma, INC. | $281.26 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Lilly USA, LLC | $150.25 | 2024-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $143.34 | 2023 | Wegovy, Saxenda |
| Idorsia Pharmaceuticals US INC | $76.67 | 2022-2023 | Quviviq |
| Dynavax Technologies Corporation | $75.58 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $72.75 | 2022-2025 | Spravato |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.57 | 2023-2024 | |
| Astellas Pharma US INC | $46.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $33.87 | 2019 | |
| Alkermes, INC. | $28.48 | 2025 | Vivitrol |
| Eisai INC. | $24.43 | 2020 | |
| Masimo Corporation | $17.32 | 2024 | Bridge |
| Endo Pharmaceuticals INC. | $16.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Pardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.